Number of U.S. adults who will develop dementia each year projected to increase from ~514,000 to 1 million; lifetime risk is 42 percent after 55 years of age.

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...

Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions ...

A new study published in Alzheimer’s & Dementia highlights a significant step forward in diagnosing Dementia with Lewy Bodies ...

Novo Nordisk ( NYSE:NVO) and Eli Lilly ( NYSE:LLY) are making headlines againthis time, for potential benefits beyond weight ...

GLP-1 users had a 12% lower risk of dementia and a reduced likelihood of psychosis and schizophrenia. “It’s hard to make a blanket recommendation, because the side effects are real," study ...